In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price ...
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthcare Services (HCSG – Research Report) and ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $109.00. The company’s ...
Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead.
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $236.00. The company ...
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of $20.00. The company’s shares closed yesterday at $7.00.
Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead.
Mayank Yadav is considered one of India’s most high-potential youngsters for the future, and a fast-bowler who could be at the heart of any team for years to come due to his combination of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results